Company Overview and News

 
Faircourt Asset Management Inc. Announces September Distributions

2018-09-15 globenewswire
TORONTO, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Faircourt Asset Management Inc., as Manager of the Faircourt Funds (TSX:FGX), (TSX:FCS.UN), is pleased to announce the monthly distributions payable on the Shares and Trust Units of the below listed Funds.
FCS.UN FRCGF FGX

 
Faircourt Asset Management Inc. Announces August Distributions

2018-08-09 globenewswire
This press release is not for distribution in the United States or over United States wire services.
FCS.UN FRCGF FGX

 
Faircourt Asset Management Inc. Announces July Distributions

2018-07-14 globenewswire
TORONTO, July 13, 2018 (GLOBE NEWSWIRE) -- Faircourt Asset Management Inc., as Manager of the Faircourt Funds (TSX:FGX), (TSX:FCS.UN), is pleased to announce the monthly distributions payable on the Shares and Trust Units of the below listed Funds.
FCS.UN FRCGF FGX

 
Faircourt Asset Management Inc. Announces June Distributions

2018-06-12 globenewswire
TORONTO, June 12, 2018 (GLOBE NEWSWIRE) -- Faircourt Asset Management Inc., as Manager of the Faircourt Funds (TSX:FGX), (TSX:FCS.UN), is pleased to announce the monthly distributions payable on the Shares and Trust Units of the below listed Funds.
FCS.UN FRCGF FGX

 
Faircourt Asset Management Inc. Announces May Distributions

2018-05-14 globenewswire
TORONTO, May 14, 2018 (GLOBE NEWSWIRE) -- Faircourt Asset Management Inc., as Manager of the Faircourt Funds (TSX:FGX), (TSX:FCS.UN), is pleased to announce the monthly distributions payable on the Shares and Trust Units of the below listed Funds.
FCS.UN FRCGF FGX

 
Faircourt Gold Income Corp. Announces Net Asset Value for Annual Redemption of Class A Shares

2018-05-01 globenewswire
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Faircourt Asset Management Inc., the Manager of Faircourt Gold Income Corp. (the “Company”) (TSX:FGX), announces today that Securityholders who tendered their Class A Shares for redemption on March 29, 2018 will be entitled to receive $3.2666 per Class A Share, which is equal to the Net Asset Value per Share calculated using a five day volume weighted average price for exchange-traded equity securities held by the Company, determined as of April 27, 2018 less the pro rata share of the aggregate of all brokerage fees, commissions and other costs relating to disposition of portfolio securities necessary to fund such redemption.
FRCGF FGX

 
Faircourt Asset Management Inc. Announces April Distributions

2018-04-13 globenewswire
TORONTO, April 13, 2018 (GLOBE NEWSWIRE) -- Faircourt Asset Management Inc., as Manager of the Faircourt Funds (TSX:FGX), (TSX:FCS.UN), is pleased to announce the monthly distributions payable on the Shares and Trust Units of the below listed Funds.
FCS.UN FRCGF FGX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...